Last updated: September 9, 2026
Ofatumumab, marketed by Novartis as Kesimpta, has become one of the fastest-growing multiple sclerosis biologics. Global sales reached approximately $3.8 billion in 2024, driven by conversion from infusion-based anti-CD20 therapies to monthly self-administered treatment. Kesimpta remains exposed to competition from Roche’s Ocrevus, TG Therapeutics’ Briumvi, oral disease-modifying therapies, and eventual biosimilar entry after biologic exclusivity and patent barriers expire.
How large is the ofatumumab market?
Ofatumumab competes in the high-value disease-modifying therapy market for relapsing forms of multiple sclerosis, including relapsing-remitting MS, clinically isolated syndrome, and active secondary progressive MS.
Kesimpta’s commercial market is concentrated in the United States, where neurologists and patients have adopted monthly subcutaneous administration as an alternative to infusion-center treatment.
| Market factor |
Effect on Kesimpta |
| Therapeutic area |
Multiple sclerosis |
| Active ingredient |
Ofatumumab |
| Brand |
Kesimpta |
| Manufacturer |
Novartis |
| Administration |
Subcutaneous injection once monthly after loading doses |
| Primary competitors |
Ocrevus, Briumvi, Tysabri, Tecfidera, Vumerity, Gilenya generics, Mavenclad |
| Core commercial advantage |
At-home administration and high-efficacy anti-CD20 mechanism |
| Main clinical constraint |
B-cell depletion, infection risk, immunoglobulin reduction, vaccination limitations |
| FDA approval |
June 2021 for adults with relapsing forms of MS |
| Regulatory exclusivity |
Twelve-year U.S. biologic reference-product exclusivity, extending to approximately 2033 from the 2021 license date |
| Likely competitive pressure |
Increasing formulary negotiation, anti-CD20 crowding, future biosimilars |
The addressable market is supported by a large prevalent MS population and continuing treatment migration toward high-efficacy therapies. Biogen, Roche, Novartis and other developers have reported increased use of early high-efficacy treatment rather than prolonged escalation from lower-efficacy drugs.
What are Kesimpta’s sales and financial trajectory?
Kesimpta has progressed from launch-stage revenue to a multibillion-dollar franchise in less than four years.
| Year |
Approximate Kesimpta sales |
Commercial development |
| 2021 |
$0.2 billion |
Initial U.S. launch year |
| 2022 |
$1.0 billion |
Rapid uptake among new starts and switches |
| 2023 |
$2.3 billion |
Broad reimbursement and increased anti-CD20 adoption |
| 2024 |
$3.8 billion |
Large-scale conversion from competing MS therapies |
| 2025 outlook |
Continued growth expected |
Growth rate likely moderates from launch-era levels |
Novartis reported Kesimpta sales of approximately $3.8 billion in 2024, with growth materially above the company’s mature-product portfolio. The product is now one of Novartis’ largest growth brands, although it remains smaller than Entresto and Cosentyx. (Novartis, 2025a)
What is driving ofatumumab revenue growth?
The principal revenue drivers are:
- New-patient initiation in relapsing MS.
- Switching from injectable, oral, and infusion therapies.
- Preference for self-administration outside an infusion center.
- Growth in high-efficacy treatment earlier in the treatment sequence.
- Expansion of Novartis’ specialty-pharmacy and patient-support infrastructure.
- Increasing physician familiarity with anti-CD20 treatment.
Kesimpta’s monthly home dosing differentiates it from Ocrevus, which requires intravenous administration in a clinical setting, and Briumvi, which also requires infusions. The convenience benefit is commercially important because infusion treatment generates administration costs, scheduling friction, travel requirements and chair-time constraints.
The product’s growth rate should decline as the addressable untreated and switch population becomes smaller. Revenue can still expand through market-share gains, international reimbursement, improved persistence and increased use earlier in the treatment pathway.
How does ofatumumab compare with Ocrevus and Briumvi?
Kesimpta competes most directly with other high-efficacy anti-CD20 therapies.
| Product |
Company |
Target |
Administration |
Commercial position |
| Kesimpta |
Novartis |
CD20 |
Monthly subcutaneous injection after loading |
Home-use convenience and growing share |
| Ocrevus |
Roche |
CD20 |
Intravenous infusion approximately every six months |
Largest established anti-CD20 MS franchise |
| Briumvi |
TG Therapeutics |
CD20 |
Intravenous infusion every 24 weeks after initial dosing |
Newer entrant competing on efficacy and dosing |
| Tysabri |
Biogen |
Alpha-4 integrin |
Intravenous or subcutaneous administration |
High efficacy, with JC-virus and PML risk management |
| Tecfidera/Vumerity |
Biogen and others |
Fumarate pathway |
Oral |
Established oral alternatives |
| Mavenclad |
Merck KGaA |
Immune reconstitution |
Short-course oral treatment |
Differentiated treatment schedule |
Ocrevus retains a substantial installed base and extensive physician experience. Kesimpta’s main competitive argument is convenience rather than a clearly established superiority claim across all patient groups. Briumvi increases price and contracting pressure in the anti-CD20 segment but has less commercial scale.
What is the FDA regulatory status of ofatumumab?
The FDA approved Kesimpta in June 2021 for adults with relapsing forms of MS. The approval was based primarily on the ASCLEPIOS I and II Phase 3 trials, which compared ofatumumab with teriflunomide. Ofatumumab reduced annualized relapse rates and MRI disease activity relative to teriflunomide. (U.S. Food and Drug Administration, 2021; Hauser et al., 2020)
The FDA-approved loading regimen consists of injections on Days 1, 7 and 14, followed by monthly maintenance dosing. The label contains warnings and precautions relating to:
- Infections.
- Hepatitis B virus reactivation.
- Reduced immunoglobulin levels.
- Injection-related reactions.
- Malignancies.
- Live or live-attenuated vaccines.
- Fetal and neonatal exposure considerations.
Ofatumumab was previously approved under the brand Arzerra for certain leukemia indications. That product was associated with GSK before Novartis obtained rights to develop ofatumumab in additional settings. Kesimpta’s commercial value comes primarily from the MS indication, not the earlier oncology use.
When does ofatumumab lose exclusivity?
U.S. exclusivity is governed by two separate concepts: biologic reference-product exclusivity and patent protection.
Biologic exclusivity
Kesimpta received twelve years of U.S. reference-product exclusivity under the Public Health Service Act. Based on the 2021 licensure date, that regulatory exclusivity runs to approximately June 2033. A biosimilar application can be filed before the end of the twelve-year period, but commercial approval and launch are constrained by regulatory exclusivity and enforceable patents. (U.S. Congress, 2010; FDA, 2024)
Patent protection
Novartis’ ofatumumab patent estate is expected to include claims directed to:
- Anti-CD20 antibody sequences and variants.
- Antibody binding and functional activity.
- Pharmaceutical compositions.
- Subcutaneous formulations.
- Dosing regimens for multiple sclerosis.
- Treatment methods involving B-cell depletion.
- Manufacturing and process controls.
The most commercially relevant patent risks will depend on the scope and enforceability of issued claims, patent-term adjustment, patent-term extension, pediatric extensions, and any biosimilar litigation settlement. Regulatory exclusivity alone does not establish the final market-entry date.
Kesimpta is a biologic and is therefore tracked primarily through the FDA Purple Book rather than the small-molecule Orange Book. Orange Book patent-listing analysis is not a complete measure of Kesimpta’s U.S. protection. (FDA, 2024)
What patent litigation and Paragraph IV risks affect ofatumumab?
Traditional Paragraph IV litigation applies to abbreviated new drug applications for small-molecule drugs. A biosimilar sponsor generally proceeds under the Biologics Price Competition and Innovation Act rather than the ANDA Paragraph IV framework.
The principal future risk is therefore a biosimilar patent challenge under the Purple Book and BPCIA procedures. A biosimilar applicant may challenge patents covering the reference product, formulation, manufacturing process or method of use. Litigation can begin before regulatory exclusivity ends, but an injunction or settlement may delay commercial launch.
As of the available public record, Kesimpta has not faced the same mature generic challenge structure seen with oral MS products. Novartis’ principal defenses are likely to be:
- Patent-validity and infringement litigation.
- Settlement agreements establishing a delayed biosimilar entry date.
- Manufacturing complexity.
- Clinical and immunogenicity comparability requirements.
- Physician and payer switching friction.
- Brand persistence and patient-support programs.
How strong is the ofatumumab patent estate?
The estate is commercially meaningful but its strength depends on claim type.
| Patent category |
Strategic value |
Likely vulnerability |
| Antibody composition claims |
Can block direct copies of the molecule |
Earlier priority dates and validity challenges |
| Formulation claims |
Can constrain the commercial injectable product |
Design-around options |
| Dosing claims |
Supports MS-specific use |
Noninfringing dosing or treatment arguments |
| Method-of-use claims |
Links ofatumumab to relapsing MS |
Limits where claims are narrower than the label |
| Manufacturing claims |
Can raise biosimilar development costs |
Process changes may avoid infringement |
| Device or delivery claims |
Supports the autoinjector presentation |
Alternative devices and administration formats |
The strongest commercial protection usually comes from the combined effect of biologic exclusivity, multiple patent families, manufacturing know-how, regulatory complexity and market entrenchment. A single composition patent is not the only determinant of launch timing.
What biosimilar risk exists for ofatumumab?
Biosimilar risk is limited in the near term but increases materially in the 2030s.
A biosimilar ofatumumab developer would need to demonstrate high similarity to Kesimpta and address a complex product profile involving:
- Antibody structure and glycosylation.
- Binding to CD20.
- B-cell depletion activity.
- Pharmacokinetics and pharmacodynamics.
- Immunogenicity.
- Subcutaneous delivery.
- Stability and container closure.
- Manufacturing consistency.
The likely first biosimilar entrants would be large biologics manufacturers and specialized developers with anti-CD20 experience. Competitors may include companies with existing rituximab or other monoclonal-antibody platforms. Biosimilar entry may initially be limited by interchangeability, payer contracting and provider confidence, especially if the reference product has strong patient persistence.
What licensing deals shaped ofatumumab’s commercial position?
Ofatumumab originated with Genmab and was licensed to GSK for development and commercialization. GSK marketed ofatumumab as Arzerra for hematologic malignancies. Novartis obtained rights through its 2015 transaction with GSK and later redirected development toward MS. (GSK, 2015)
The strategic value of the transaction was the ability to reuse a clinically validated anti-CD20 antibody in a larger chronic-disease market. MS offered a broader and more durable commercial opportunity than the original oncology franchise, provided that subcutaneous administration and monthly dosing could be differentiated from infusion-based anti-CD20 products.
What is the geographic market outlook for ofatumumab?
The United States remains the primary revenue market because of its large specialty-drug spending base and rapid adoption of high-efficacy MS therapies. Europe contributes substantial volume but faces greater price regulation, health-technology-assessment requirements and national reimbursement variation.
United States
The U.S. market supports:
- Higher net pricing than most international markets.
- Broad specialty-pharmacy distribution.
- Direct-to-consumer promotion.
- Rapid switching from infusion and oral therapies.
- Strong patient-support programs.
Europe
European uptake depends on country-specific reimbursement and treatment sequencing. Some markets require failure of other therapies before reimbursement, limiting early-line penetration. Price referencing can also reduce net price over time.
Other markets
Japan, Canada, Australia and selected emerging markets provide incremental growth. Their contribution is constrained by regulatory timing, reimbursement restrictions and lower net prices.
What are the main financial risks to Kesimpta?
The major risks are commercial rather than near-term regulatory.
First, Ocrevus has an established physician base and a long dosing interval. Second, Briumvi gives payers another anti-CD20 option for price negotiations. Third, oral agents remain attractive to patients who prefer tablets over injections or infusions. Fourth, anti-CD20 class safety monitoring can limit use in patients with recurrent infections, low immunoglobulin levels or vaccination needs.
Novartis also faces gross-to-net pressure. Rebates, specialty-pharmacy fees, copay support and payer restrictions can reduce net sales even if prescription volume continues to grow.
The key financial indicators are:
- New-patient starts.
- Switching share from Ocrevus.
- Persistence after the first year.
- U.S. refill volume.
- Net price after rebates.
- International reimbursement expansion.
- Anti-CD20 class share of the MS market.
- Timing of biosimilar patent settlements.
What generic launch scenarios exist for ofatumumab?
Base case
Kesimpta continues to grow through the late 2020s, with slowing annual growth as the product reaches a larger share of the anti-CD20 market. No material U.S. biosimilar revenue appears before the early 2030s.
Downside case
Ocrevus, Briumvi and oral therapies increase contracting pressure. Kesimpta growth slows before the product reaches peak revenue. Payer restrictions shift treatment toward lower-cost alternatives.
Long-term erosion case
One or more biosimilars launch after regulatory exclusivity and patent settlements. Price erosion develops gradually, with the largest impact in government and managed-care channels. Subcutaneous convenience and patient persistence protect part of the franchise.
Upside case
Novartis expands early-line adoption, improves persistence, wins favorable payer positioning and preserves premium pricing through device, formulation and service differentiation.
Key Takeaways
- Kesimpta generated approximately $3.8 billion in sales in 2024.
- Revenue growth has been driven by conversion to monthly self-administered anti-CD20 treatment.
- Ocrevus is the largest direct competitor; Briumvi adds further anti-CD20 pricing pressure.
- U.S. biologic reference-product exclusivity runs approximately to 2033 from the 2021 FDA license.
- Kesimpta is tracked through the Purple Book, not the traditional Orange Book framework.
- Future biosimilar litigation will likely involve composition, formulation, dosing, manufacturing and method-of-use patents.
- The highest-value commercial metrics are new starts, switching share, persistence, payer access and net price.
- Revenue growth should moderate as the product matures, but the franchise has a long runway before biosimilar erosion becomes material.
FAQs About Ofatumumab Market and Exclusivity
Is Kesimpta a blockbuster biologic?
Yes. Kesimpta exceeded $1 billion in annual sales in 2022 and reached approximately $3.8 billion in 2024, making it a major Novartis growth product.
Does ofatumumab compete directly with Ocrevus?
Yes. Both are anti-CD20 therapies used for relapsing MS. Kesimpta is administered monthly by subcutaneous injection, while Ocrevus is administered by intravenous infusion approximately every six months.
Is there a generic version of Kesimpta?
No conventional generic exists because ofatumumab is a biologic. Future competition would come through biosimilar applications rather than traditional ANDAs.
What is the main advantage of Kesimpta over infusion therapies?
The main advantage is at-home monthly administration, which avoids scheduled infusion-center visits and may reduce treatment-related logistical burden.
Can Novartis extend ofatumumab exclusivity beyond 2033?
Commercial protection may extend beyond the twelve-year biologic exclusivity period through valid patents, pediatric extensions, patent-term adjustments, formulation claims, manufacturing claims and litigation settlements. Regulatory exclusivity and patent expiration dates are separate legal events.
References
-
GSK. (2015). GSK and Novartis transaction completes. GlaxoSmithKline.
-
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Siegel, D., Galetta, S. L., Garren, H., & Kappos, L. (2020). Ofatumumab versus teriflunomide in multiple sclerosis. New England Journal of Medicine, 383(6), 546-557. https://doi.org/10.1056/NEJMoa1917246
-
Novartis. (2025a). Annual report 2024. Novartis AG.
-
Novartis. (2025b). Fourth quarter and full-year 2024 results. Novartis AG.
-
U.S. Congress. (2010). Patient Protection and Affordable Care Act, Title VII, Biologics Price Competition and Innovation Act. 42 U.S.C. § 262.
-
U.S. Food and Drug Administration. (2021). Kesimpta prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
